We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

ACKB:EURONEXT BRUSSELSAckermans & van Haaren NV Analysis

Data as of 2026-07-02 - not real-time

€278.80

Latest Price

5/10Risk

Risk Level: Medium

Executive Summary

Ackermans & Van Haaren trades at €278.8, roughly 27% above the DCF‑derived fair value of €218, indicating a short‑term premium. The stock’s trailing P/E of 15.4 is well below the industry average of 31.8, suggesting relative valuation appeal, while the RSI sits at 48 and the MACD histogram has turned negative, hinting at a possible near‑term pullback despite the overall bullish trend and price staying above the 20‑ and 50‑day SMAs. Dividend sustainability looks strong – a €4.60 payout (1.61% yield) with a modest 21% payout ratio is backed by solid operating cash flow of €1.0 bn and a free cash flow of €540 m. Volatility remains elevated at 22.5% over 30 days, but the low beta of 0.40 points to limited market‑wide sensitivity.
The recent shareholder meeting confirmed a €4.60 dividend and the Q1 trading update highlighted a “strong start” and reaffirmed guidance, underscoring confidence in earnings continuity. With a diversified business spanning marine engineering, private banking, real estate and energy, the company benefits from multiple cash‑generating streams, though revenue contracted 7.3% YoY. The balance sheet shows a debt‑to‑equity of 30.5%, manageable given ample cash reserves of €2.2 bn. Overall, the stock appears overvalued on a price‑based basis, yet its fundamentals and dividend profile provide a cushion for longer‑term investors.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Price trading above fair value
  • Bearish MACD crossover
  • Elevated short‑term volatility

Medium Term

1–3 years
Neutral
Model confidence: 7/10

Key Factors

  • Strong dividend yield with low payout ratio
  • Stable cash flow and manageable debt
  • Confirmed earnings guidance for 2026

Long Term

> 3 years
Positive
Model confidence: 8/10

Key Factors

  • Diversified business model across multiple sectors
  • Attractive relative valuation versus industry peers
  • Sustainable dividend and solid balance sheet

Key Metrics & Analysis

Financial Health

Revenue Growth-7.30%
Profit Margin9.94%
P/E Ratio15.4
ROE11.02%
ROA2.43%
Debt/Equity30.48
P/B Ratio1.6
Op. Cash Flow€1.0B
Free Cash Flow€540.6M
Industry P/E31.8

Technical Analysis

TrendBullish
RSI48.2
Support€262.00
Resistance€290.40
MA 20€279.27
MA 50€278.85
MA 200€252.05
MACDBearish
VolumeIncreasing
Fear & Greed Index91.8

Valuation

Fair Value€218.12
Target Price€304.14
Upside/Downside9.09%
GradeOvervalued
TypeValue
Dividend Yield1.61%

Risk Assessment

Beta0.40
Volatility22.53%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.